AVIR
Atea Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.85
+0.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 38.3M | — | 83.4M | 70.1M | 62.4M |
| Gross Profit | (38.3M) | — | (83.4M) | (70.1M) | (62.4M) |
| Operating Expenses | |||||
| R&D Expense | 155.4M | 148.0M | 145.4M | 132.8M | 88.8M |
| SG&A Expense | 28.2M | 32.9M | 48.8M | 49.9M | 48.7M |
| General & Admin Expense | 28.2M | 32.9M | 48.8M | 49.9M | 48.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (38.3M) | — | (84.7M) | (88.7M) | (69.3M) |
| Total Operating Expenses | 145.3M | 180.9M | 109.6M | 94.1M | 68.3M |
| Cost and Expenses | 183.6M | 180.9M | 192.9M | 164.2M | 130.7M |
| Operating Income (EBIT) | (183.6M) | (180.9M) | (192.9M) | (164.2M) | (130.7M) |
| Non-Operating | |||||
| Interest Income | 9.6M | 16.4M | 25.5M | 29.2M | 11.2M |
| Interest Expense | — | — | — | — | 11.2M |
| Net Interest Income | 9.6M | 16.4M | 25.5M | 29.2M | — |
| Other Non-Op Income/Expense | 11.8M | 16.4M | 25.5M | 29.2M | 11.2M |
| Non-Operating Income (excl Interest) | (11.8M) | (16.4M) | (60.7M) | (44.2M) | (19.5M) |
| EBT (Pre-Tax Income) | (171.8M) | (164.5M) | (167.5M) | (134.9M) | (119.5M) |
| Income Tax Expense | (6.5M) | (6.2M) | 925.0K | 1.0M | (3.6M) |
| Bottom Line | |||||
| Net Income | (165.3M) | (158.3M) | (168.4M) | (136.0M) | (115.9M) |
| Earnings from Cont. Ops | (165.3M) | (158.3M) | (168.4M) | (136.0M) | (115.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (165.3M) | (158.3M) | (168.4M) | (136.0M) | (115.9M) |
| Per Share | |||||
| Basic EPS | ($2.08) | ($1.94) | ($2.00) | ($1.63) | ($1.39) |
| Diluted EPS | ($2.08) | ($1.94) | ($2.00) | ($1.63) | ($1.39) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 80.1M | 81.5M | 84.3M | 83.4M | 83.2M |
| Diluted Shares Outstanding | 80.1M | 81.5M | 84.3M | 83.4M | 83.2M |
| Profitability Metrics | |||||
| EBITDA | (171.3M) | (164.1M) | (131.8M) | (119.6M) | (110.8M) |
| D&A | 520.0K | 416.0K | 416.0K | 416.0K | 260.0K |
| EBIT | (171.8M) | (164.5M) | (132.2M) | (120.0M) | (111.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026